Skip to main content

Table 2 Responses

From: Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer

  Results N %
CNS
N = 22
Complete Response 0 0
Partial Response 2 9
 Parenchymal 0 0
 Leptomeningeal 2 9
Stable Disease 10 45
 Parenchymal 7 32
 Leptomeningeal 1 5
 Parenchymal + leptomeningeal 2 9
Disease control (partial response + stable disease) 12 55
Progression Disease 10 45
 Parenchymal 7 32
 Leptomeningeal 1 5
 Parenchymal + leptomingeal 2 9
Other sites
N = 18
Complete Response 0 0
Partial Response 0 0
Stable Disease 7 39
Progression Disease 11 61